ClinicalTrials.gg
RecruitingNCT07767708IRM-POPBUpdated Aug 17, 2026

Development of Diffusion MRI and Tractography Technique for the Detection of Nerve Lesions in Brachial Plexus Injuries

An interventional study of Performing an MRI in Obstetric Brachial Plexus Palsy, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 14 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
14 Years to 30 Years
Sex
All
01

Study summary

The objective of this prospective study is to contribute to improving the management of patients with obstetric brachial plexus palsy.

The main objective is the characterization of the microstructure by diffusion MRI in patients with a history of unoperated obstetrical brachial plexus palsy.

Read the detailed description

The brachial plexus is a collection of nerve fibers that provides all sensory and motor functions of the entire upper limb. Its anatomy is particularly complex.

Obstetric brachial plexus palsy (OBP) is defined as flaccid paralysis of the upper limb, occurring at birth, related to forceful manipulation of the fetus for its delivery. This neonatal condition is not uncommon.

While most cases of OBP appear to recover spontaneously, children with incomplete recovery may have significant functional limitations related to muscle weakness, more or less associated with soft tissue retractions. Muscle weakness will induce an imbalance that can affect bone growth and joint development.

Simple stretching or neurapraxia almost always progresses spontaneously and favorably. Avulsion injuries, on the other hand, cannot heal spontaneously and therefore require surgery to restore upper limb function. The aim of this study is that DTI (Diffusion Tensor Imaging) imaging of the brachial plexus allows access to the entire brachial plexus in order to establish a lesion assessment and a powerful tool to aid in the decision for surgical exploration.

To date, there is no standard imaging technique for exploring the brachial plexus.

Diffusion tensor imaging is a new acquisition technique that tracks the movement of water molecules in all three spatial planes.

Tractography, or fiber tracking, is an acquisition and analysis technique performed using diffusion tensor imaging (DTI) MRI data.

An MRI protocol has been developed for analyzing the brachial plexus based on pilot MRI scans performed at the Brain and Spine Institute. Subjects selected for this study will undergo MRI scans using different sequences from this protocol. Image processing and tractography sequences will allow for precise analysis of the function and structure of the brachial plexus nerves and characterization of lesions in affected subjects compared to the unaffected contralateral side. The hypothesis of this research is that DTI imaging of the brachial plexus will allow a better understanding of POPB by establishing a precise lesion assessment in association with clinical data.

This is a single-center, non-randomized feasibility study involving MRI imaging analyses and requiring no changes to the patient's usual care.

Imaging data from each subject will be analyzed and statistically compared. Each patient will serve as their own control (comparison between the healthy and pathological plexus).

Imaging data from each subject can be analyzed and statistically compared.

02

Conditions studied

  • Obstetric Brachial Plexus Palsy

Browse trials for

Keywords

  • obstetric brachial plexus paralysis
  • magnetic resonance imaging
  • diffusion tensor imaging
  • tractography
03

In context

Paralysis

147 studies on the registry are indexed under Paralysis; 40 are open to participants now.

This study's planned enrollment of 8 is below the median of 18 across 113 interventional studies indexed under Paralysis.

Browse Paralysis studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,592 studies on the registry; 1,033 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 14 to 30 years
  • Consulted by the Orthopedics Department at Armand Trousseau Hospital
  • Diagnosed and monitored by Armand Trousseau Hospital for obstetrical brachial plexus palsy (OBBP)
  • Having a single, unoperated lesion (lesions are very different and only exceptionally affect all the roots bilaterally).
  • Not suffering from bone or neurological pathology unrelated to OBP
  • Patients affiliated with or entitled to a social security scheme
  • Patients who have received informed information and have signed, with the investigator, a consent form to participate in the study
  • Parents/legal guardians who have received informed information and have co-signed, with the investigator, a consent form to participate in the study, for minor patients

Exclusion criteria

Exclusion Criteria:

  • History of rheumatoid pathologies, constitutional bone diseases, past or current pathologies affecting the arm or neck unrelated to the obstetric brachial plexus, any history of neoplasia or radiographic appearance consistent with a neoplastic fracture
  • Current pregnancy
  • Inability to perform the MRI examination (presence of a , incapacitating pain, or claustrophobia)
  • Large tattoo present in the area of interest (artifacts)
  • Patients deprived of liberty, or under guardianship/curatorship
  • Patients receiving medical assistance (AME)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Other
    One group

    Other: Performing an MRI

Interventions

  • OtherPerforming an MRI

    Various MRI sequences were performed (without injection) according to a new protocol developed at the ICM. This acquisition protocol consists of anatomical and diffusion sequences lasting approximately 1 hour. The acquisitions were performed in a 3T MRI scanner, in the supine position with the palms facing upwards. Gadolinium was not used in our study.

06

What researchers measure

Primary outcomes

  1. Characterization of the microstructure by MRI diffusion in patients with a history of unoperated obstetrical brachial plexus palsy (OBBP)

    Extraction of diffusion tensor parameters (measurement of signal anisotropy ) along the different nerves constituting the brachial plexus, reconstructed using tractography.

    Time frame: 3 months max.

  2. Characterization of the microstructure by MRI diffusion in patients with a history of unoperated obstetrical brachial plexus palsy (OBBP)

    Extraction of diffusion tensor parameters, measurement of diffusivity, along the different nerves constituting the brachial plexus, reconstructed using tractography

    Time frame: 3 months max.

  3. Characterization of the microstructure by MRI diffusion in patients with a history of unoperated obstetrical brachial plexus palsy (OBBP)

    Comparison of metrics (Anitropy Fraction, Mean Diffusion) of healthy versus injured nerves. Each plexus is manually segmented by ITK SNAP in order to extract the nerve pathways of each plexus.

    Time frame: 3 months max.

  4. Characterization of the microstructure by MRI diffusion in patients with a history of unoperated obstetrical brachial plexus palsy (OBBP)

    Description of FA, MD parameter measurements on tractography sequences along the complete pathway of the brachial plexus nerves

    Time frame: 3 months max.

Secondary outcomes

  1. Determination of the anatomical location of POPB lesions (trunk, terminal branches, etc.) in comparison with the contralateral healthy side of the patients

    Compare by MRI diffusion anatomical and diffusion measurements between different subjects

    Time frame: 3 months max.

  2. Analyze the plexus fibers altered by the neuroma in the affected plexuses

    Analysis of the qualitative characteristics of the axons studied in the plexus area of the neuroma in affected subjects (visual analysis of the roots affected by the neuroma compared with the healthy side, as well as measurement of the volumes in voxels)

    Time frame: 3 months max.

  3. Analyze the plexus fibers altered by the neuroma in the affected plexuses

    Analysis of the quantitative characteristics of the axons studied in the plexus area of the neuroma in affected subjects (fractional anisotropy, mean diffusion, axial diffusion and radial diffusion)

    Time frame: 3 months max.

  4. Establish anatomoclinical relationships with the data from the specific and in-depth clinical examination carried out in consultation

    Analysis of the apparent lesions visible on MRI

    Time frame: 3 months max.

  5. Analyze the feasibility of the DTI MRI acquisition protocol

    Feasibility : acquisition time (the acquisition time required to obtain image quality sufficient for post-MRI analysis),

    Time frame: 3 months max.

  6. Analyze the feasibility of the DTI MRI acquisition protocol

    Feasibility: imaging quality

    Time frame: 3 months max.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 12 months after the start.

Of 48 non-industry interventional studies with no phase under Paralysis, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 133. This study's planned 12 months is below that.

Counting every sponsor, half of 58 studies reached it within 41 months; a quarter within 12 and three quarters within 133.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2025
First posted
Aug 17, 2026
StartActual
Jan 9, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Feb 2027
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07767708
Responsible party
Sponsor
First posted
Aug 17, 2026
Start date
Jan 9, 2026
Primary completion
Jan 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Aug 17, 2026

Study contacts

Manon BACHY-RAZZOUK, PU-PH
Contact
manon.bachy@aphp.fr
00 33 1 44 73 69 37
Mathilde PAYEN, PH
Contact
mathilde-payen@hotmail.fr
00 33 2 32 88 89 90
Manon BACHY-RAZZOUK, PU-PH
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion